Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/14/2005EP1604661A1 Remedy for corneal ulcer
12/14/2005EP1604660A1 Medicinal composition for treating infection with drug-resistant staphylococcus aureus
12/14/2005EP1604659A1 Tablet containing water-absorbing amino acid
12/14/2005EP1604658A2 Pharmaceutical composition comprising ibuprofen and prochlorperazine
12/14/2005EP1604657A1 Pharmaceutical formulation of a stable Formoterol-containing solution for use in inhalation therapy and method of preparing it
12/14/2005EP1604656A1 Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
12/14/2005EP1604655A1 Novel use of peptide compounds for treating pain in trigeminal neuralgia
12/14/2005EP1604654A1 Novel use of peptide compounds for treating dyskinesia
12/14/2005EP1604653A1 Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
12/14/2005EP1604651A1 Transdermal patches and methods for delivering testosterone
12/14/2005EP1604650A2 Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid
12/14/2005EP1604037A1 Medical use of ras antagonists for the treatment of capillary malformation
12/14/2005EP1604022A2 Modulation of gene expression using dna-rna hybrids
12/14/2005EP1604017A2 Cell preparation and use of the preparation for treating joints and cartilage defects, and methods for the production thereof
12/14/2005EP1604009A2 Method for identifying risk of melanoma and treatments thereof
12/14/2005EP1603941A1 Inhibitors of extracellular hsp90
12/14/2005EP1603934A1 Ethercarboxylic acid ester of sterol or stanol
12/14/2005EP1603933A2 Nitrosated and nitrosylated compounds, compositions and methods of use
12/14/2005EP1603919A1 7-imino derivatives of camptothecin having antitumor activity
12/14/2005EP1603915A1 SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
12/14/2005EP1603914A1 Compounds having activity at 5ht2c receptor and uses thereof
12/14/2005EP1603912A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
12/14/2005EP1603911A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
12/14/2005EP1603910A1 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
12/14/2005EP1603909A2 Linear chain substituted monocyclic and bicyclic derivatives as factor xa inhibitors
12/14/2005EP1603907A1 Substituted pyrido(1,2-a)pyrimidines and their use as nos inhibitors
12/14/2005EP1603905A1 Vanilloid receptor ligands and their use in treatments
12/14/2005EP1603901A1 Tetrahydropyran compounds as tachykinin antagonists
12/14/2005EP1603900A2 Antiprotozoal imidazopyridine compounds
12/14/2005EP1603897A1 Pyrazole compounds useful in the treatment of inflammation
12/14/2005EP1603896A2 Cxcr3 antagonists
12/14/2005EP1603894A1 Pharmacologically active novel dauer pheromone compound for controlling aging and stress and method for isolating and characterizing the same
12/14/2005EP1603890A1 TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES
12/14/2005EP1603889A1 Novel crystalline forms of lamotrigine
12/14/2005EP1603887A1 Hiv replication inhibiting pyrimidines and triazines
12/14/2005EP1603884A2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
12/14/2005EP1603881A2 Substituted thiophenes with antibacterial activity
12/14/2005EP1603879A2 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
12/14/2005EP1603872A1 S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt
12/14/2005EP1603870A1 S- 2- (1-iminoethyl)amino ethyl -2-methyl-l-c ysteine salicylate monohydrate crystalline salt
12/14/2005EP1603869A1 S- 2- (1-iminoethyl)amino ethyl -2-methyl-l-c ysteine maleate form ii crystalline salt
12/14/2005EP1603864A2 Diphenylethylene compounds and uses thereof
12/14/2005EP1603860A2 Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
12/14/2005EP1603606A2 Endovascular implant with an at least sectional active coating made of radjadone and/or a ratjadone derivative
12/14/2005EP1603597A2 Oxycodone conjugates with lower abuse potential and extended duration of action
12/14/2005EP1603595A1 Pharmaceutical composition for treatment of drug dependence
12/14/2005EP1603593A2 Pharmaceutical composition
12/14/2005EP1603583A2 Use of incense or hydrogenation products for preventing and/or treating a cerebral ischemia and/or cerebral traumatic lesion
12/14/2005EP1603580A1 Composition for administration of iron for the treatment of restless legs syndrome
12/14/2005EP1603579A2 Compositions and methods for use of alginate dural sealants
12/14/2005EP1603578A2 Cystitis treatment with high dose chondroitin sulfate
12/14/2005EP1603577A1 Compounds for the treatment of pain
12/14/2005EP1603576A1 Use of adenosine receptor agonists in therapy
12/14/2005EP1603575A2 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
12/14/2005EP1603574A1 Medicament or nutriceutical combining a soluble poorly-absorbed saccharide and an antiflatulent from the siloxane group
12/14/2005EP1603573A2 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
12/14/2005EP1603572A1 Lactam-containing cyclic diamines and derivatives as factor xa inhibitors
12/14/2005EP1603571A2 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
12/14/2005EP1603570A2 Aminoheteroaryl compounds as protein kinase inhibitors
12/14/2005EP1603569A1 Method of treating cancer with quinolone carboxylic acid derivatives
12/14/2005EP1603568A2 Isoquinoline derivatives and methods of use thereof
12/14/2005EP1603567A2 Tetracyclic benzamide derivatives and methods of use thereof
12/14/2005EP1603566A1 Use of isoquinoline derivatives for treating cancer and map kinase related diseases
12/14/2005EP1603565A1 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
12/14/2005EP1603564A2 Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic neuropathological or psychogenic pain symptoms
12/14/2005EP1603563A1 Resonance modulator for diagnosis and therapy
12/14/2005EP1603562A2 Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
12/14/2005EP1603561A2 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
12/14/2005EP1603560A1 Topical immunotherapy and compositions for use therein
12/14/2005EP1603559A1 Pharmaceutical composition for intracellular acidification with cis-urocanic
12/14/2005EP1603557A2 Synthesis of peloruside a and analogs thereof for use as antitumor agents
12/14/2005EP1603556A2 Sod mimic multifunctional compounds for treating inflammatory bowel disease
12/14/2005EP1603555A2 Halogenated triptolide derivatives as immunomodulators and anticancer agents
12/14/2005EP1603554A1 Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
12/14/2005EP1603553A2 Pharmaceutical compositions of cetp inhibitors
12/14/2005EP1603552A1 Carnitine retention
12/14/2005EP1603551A2 Use of omega-3-fatty acids in the treatment of diabetic patients
12/14/2005EP1603550A1 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid
12/14/2005EP1603549A2 Improved bioavailability and improved delivery of acidic pharmaceutical drugs
12/14/2005EP1603548A2 Method and composition for treating neurodegenerative disorders
12/14/2005EP1603547A1 Trospium containing compositions
12/14/2005EP1603546A1 Glycinamide derivative for inhibiting hiv replication
12/14/2005EP1603545A2 Method of treatment of disease using an adenosine a1 receptor antagonist
12/14/2005EP1603544A1 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine
12/14/2005EP1603543A1 Therapeutic compositions
12/14/2005EP1603542A1 Treatment and/or prevention of non-viral epithelial damage
12/14/2005EP1603541A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
12/14/2005EP1603537A2 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
12/14/2005EP1603533A1 Opioid delivery system
12/14/2005EP1603532A1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
12/14/2005EP1603531A2 Gel composition and method for treatment of vaginal infections
12/14/2005EP1603520A1 Composition comprising particulate zinc materials having a defined crystallite size
12/14/2005EP1603513A2 Treatment using dantrolene
12/14/2005EP1603510A2 Methods of improving skin quality
12/14/2005EP1603509A2 Method and system for administering a drug
12/14/2005EP1603499A2 Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
12/14/2005EP1603485A2 Bioactive stents and methods for use thereof
12/14/2005EP1603451A2 Amyloid plaque as a target for therapeutics that function by blocking or disrupting chitin synthesis or activity
12/14/2005EP1603450A2 Type 1 ryanodine receptor-based methods
12/14/2005EP1603448A2 Serotonin and catecholamine system segment optimization technology
1 ... 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 ... 7860